

NEWS RELEASE

## Pipeline Therapeutics to Participate in Upcoming Investor Conferences

10/4/2023

SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences:

- Jefferies Biotech CNS/Neuro Summit, October 11-12, 2023, NY, NY
- 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, October 17-18, 2023
- Leerink Virtual Biopharma Private Company Connect, October 25-26, 2023

### About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company's lead wholly-owned program, PIPE-791, an LPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases.

For more information, please visit [www.pipelinetherapeutics.com](http://www.pipelinetherapeutics.com) and engage with us on LinkedIn.

### Company Contact:

Peter Slover

CFO

[ir@pipeline-tx.com](mailto:ir@pipeline-tx.com)

**Investor Contact:**

Amy Conrad

**amy@juniper-point.com**

Source: Pipeline Therapeutics